Zepbound / Mounjaro (Tirzepatide)

Tirzepatide is a medicine used to help manage blood sugar levels in people with type 2 diabetes. It works by mimicking natural hormones that help control sugar in the body. It's usually taken once a week.

Brand names:Mounjaro, Zepbound
Medication

What people taking Zepbound / Mounjaro (Tirzepatide) report

Every report comes from a Lived member, sent anonymously.

Have you tried Zepbound / Mounjaro (Tirzepatide) for Weight Loss?

NameHow it went

About Zepbound / Mounjaro (Tirzepatide)

What It's For

Tirzepatide is a once-weekly injected medicine sold as Mounjaro and Zepbound, two brands with the same active ingredient but different approved uses. Alongside diet and exercise, Mounjaro treats type 2 diabetes, improving blood sugar control in adults and children 10 and older. In adults with type 2 diabetes at high risk, it also lowers the chance of heart attack, stroke and heart-related death. Zepbound is for adults: with diet and activity, it helps people with obesity, or overweight plus a weight-related condition, lose weight and keep it off long term. It also treats moderate to severe obstructive sleep apnea, repeated breathing pauses during sleep, in adults with obesity.

How It Works

Tirzepatide mimics two hormones the gut releases after eating, GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These signals act on appetite pathways in the brain, so people feel full sooner and eat less. The medicine also helps the pancreas release insulin when blood sugar is high and slows how quickly the stomach empties. Together these lower blood sugar in people with diabetes. Semaglutide, the ingredient in Ozempic and Wegovy, mimics GLP-1 alone; how much the added GIP action contributes in people is still being studied.

Dosage & Administration

Both brands are injected under the skin once a week, into the belly or thigh, or the upper arm if someone else gives it, from a pen or vial. Treatment starts at 2.5 mg, a dose for getting used to the medicine rather than for its full effect. The prescriber raises it in steps at least 4 weeks apart so the digestive system can adjust. Some pens, called KwikPens, hold several doses. A multi-dose pen is for one person only, even with a new needle, because sharing can spread blood-borne infections.

Side Effects

Nausea, diarrhea, vomiting, constipation and indigestion are the most common side effects, mostly in the first months and after dose increases, and they are the main reason people stop. Smaller meals, avoiding large or high-fat ones, can ease nausea and diarrhea. Vomiting or diarrhea that will not stop can dehydrate and harm the kidneys, so call the prescriber right away. For severe stomach pain that will not go away, sometimes reaching the back, stop the medicine and call right away: it can signal pancreatitis (an inflamed pancreas). Upper-belly pain with fever, or yellow skin or eyes, can point to a gallbladder problem and also needs a call right away.

Interactions & Warnings

Both brands carry a boxed warning because tirzepatide caused thyroid tumors in rats; whether it does in people is unknown. Report a neck lump or lasting hoarseness. It is not used with a personal or family history of medullary thyroid cancer, with multiple endocrine neoplasia type 2 (MEN 2), an inherited condition, or after a serious allergic reaction to tirzepatide or its ingredients. A serious allergic reaction, with face or throat swelling or trouble breathing, needs 911. Insulin or a sulfonylurea (an older diabetes pill) taken with it raises the risk of low blood sugar, sometimes severe, so those doses may be lowered. Birth control pills may work less well for 4 weeks after starting and after each dose increase, so add a barrier method or use a non-oral one. Tell the care team before anesthesia or sedation, because stomach contents can be inhaled into the lungs. Zepbound is stopped once pregnancy is recognized; Mounjaro is used only if the benefit outweighs the risk. Neither suits severe gastroparesis (very slow stomach emptying), and Zepbound is not combined with other tirzepatide or GLP-1 medicines. Compounded tirzepatide is not approved by the US Food and Drug Administration, so the agency has not reviewed it for safety, effectiveness or quality.

What to Expect

Because the dose climbs in 4-week steps, effects build over months. In the main 72-week trial, adults without diabetes lost about 15 to 21 percent of their body weight on average, against about 3 percent on placebo; people with type 2 diabetes lost somewhat less. In the sleep apnea trials, breathing pauses fell by about half or more. It is usually long-term: people switched to placebo after 36 weeks regained much of the weight over the next year, while those who stayed on it kept losing. Follow-up visits during dose increases check benefit and side effects; people with diabetes also track blood sugar, and those with diabetic eye disease report vision changes, since a rapid drop in blood sugar can temporarily worsen it.

Questions to Ask Your Doctor

  1. 1.Which brand fits my goals, and how does it compare with semaglutide for me?
  2. 2.How will we judge whether it is working, and over what period?
  3. 3.If stomach side effects are hard to tolerate, can we slow the dose increases?
  4. 4.Do any of my current medicines, such as birth control pills or diabetes medicines, need to change?
  5. 5.If I stop someday, what would the plan be for keeping the weight off?

Last reviewed • Oct 2026

Educational content, not medical advice.